Results 101 to 110 of about 6,500,274 (300)

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

open access: yesMolecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez   +5 more
wiley   +1 more source

2012 Assisted Reproductive Technology Report \u2014 Graphs and Charts

open access: yes
Graphs and charts from the 2012 Assisted Reproductive Technology National Summary Report provide an in-depth picture of the type, number, and outcome of ART cycles performed in U.S. fertility clinics.

core  

2013 Assisted Reproductive Technology National Summary Report [PDF]

open access: yes
The data for this national report come from the 467 fertility clinics in operation in 2013 that provided and verified data on the outcomes of all ART cycles started in their clinics. Of the 190,773 ART cycles performed in 2013 at these reporting clinics,

core  

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

open access: yesMolecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth   +17 more
wiley   +1 more source

2016 Assisted Reproductive Technology Report \u2014 Graphs and Charts

open access: yes
Graphs and charts from the 2016 Assisted Reproductive Technology National Summary Report provide an in-depth picture of the type, number, and outcome of ART cycles performed in U.S. fertility clinics.

core  

2017 Assisted Reproductive Technology National Summary Report [PDF]

open access: yes
The data for this national report come from the 448 US fertility clinics in operation in 2017 that provided and verified data on the outcomesof all ART cycles started in their clinics.echnology Fertility Clinic Success Rates Report. Of the 284,385 cycles

core  

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

Assisted reproductive techniques in the prevention of mitochondrial diseases

open access: yesUniversidad Médica Pinareña, 2020
Introduction: the mitochondrion is an important organelle that has its own DNA that is sensitive to mutations. These mutations can cause mitochondrial diseases, a heterogeneous group that suggests mitochondrial dysfunction.
Felipe De Jesús López-Catá   +2 more
doaj   +2 more sources

2013 Assisted Reproductive Technology Report \u2014 Graphs and Charts

open access: yes
Graphs and charts from the 2013 Assisted Reproductive Technology National Summary Report provide an in-depth picture of the type, number, and outcome of ART cycles performed in U.S. fertility clinics.

core  

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy